Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
The goal of this observational study is to learn about the changes of antibodies and inhibitors against the coagulation factor VIII in patients with severe hemophilia A receiving emicizumab therapy. No additional visits or procedures are planned. Patients in this study will continue to receive their routine care and analysis will be done from left over samples from routine visits.
Enrollment
Sex
Volunteers
Inclusion criteria
Exclusion criteria
100 participants in 3 patient groups
Loading...
Central trial contact
Christoph Koenigs, PD Dr. Dr; Stephan Schultze-Strasser, Dr.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal